Welcome to our dedicated page for Tenon Medical SEC filings (Ticker: TNON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenon Medical, Inc. filings document its medical-device business, public securities, and material events tied to sacroiliac joint treatment products. Current Reports on Form 8-K cover financial results, unaudited revenue releases, FDA-cleared product updates, and corporate communications related to the Catamaran System and SImmetry® portfolio.
The filing record also discloses securities purchase agreements, senior convertible notes, private placements of common stock and warrants, restricted stock unit grants under the 2022 Equity Incentive Plan, annual meeting voting matters, Nasdaq listing-compliance notices, and amended acquisition disclosures with financial statements and pro forma information for the SiVantage asset acquisition.
Tenon Medical, Inc. (TNON) reported that its Chief Financial Officer, Kevin Williamson, had 30 restricted stock units vest and convert into 30 shares of common stock on September 8, 2026, from RSUs granted November 5, 2024 and adjusted for a 1-for-35 reverse stock split effected August 10, 2026. On September 9, 2026, 11 of the resulting common shares were delivered or withheld at a price of $3.45 per share to pay the associated tax liability.
Tenon Medical, Inc. (TNON) reported that it has fully repaid its outstanding original issue discount senior convertible promissory notes, which had an aggregate principal balance of approximately $5.16 million, on September 9, 2026, ahead of their September 11, 2026 maturity date. The Notes were issued on March 11, 2026.
The company states that this early repayment strengthens its balance sheet and removes the potential conversion of the Notes into common stock at a discount to market prices, which would have created dilution. Tenon highlights that eliminating this obligation provides greater financial flexibility to support commercialization of its SI Joint fusion systems and broader growth initiatives.
Tenon Medical, Inc. (TNON) reported that major shareholder HRT FINANCIAL LP, a ten percent owner, both bought and sold Tenon common stock in early September 2026. On September 3, HRT FINANCIAL LP purchased 1,658 shares at $3.98 per share, then on September 4 sold 1,506 shares at $3.70 per share in open market or private transactions. Overall, these reported trades represent a small net purchase of 152 shares, and no post-transaction share balance is stated.
Tenon Medical, Inc. (TNON) reports a private exempt offering of securities under Regulation D, claiming the Rule 506(b) exemption. The company indicates a total amount sold of $3,000,000 with $0 remaining to be sold, suggesting the offering has been fully subscribed as reported here.
The offering includes equity, options, warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. WallachBeth Capital LLC is identified in a sales compensation role, and stated finders’ fees are $0. The notice is signed on behalf of Tenon Medical by Chief Executive Officer and President Steven M. Foster.
Tenon Medical, Inc. (TNON) had insider activity reported by large shareholder HRT Financial LP. On September 1, 2026, HRT purchased 1,790 shares of common stock at $4.57 per share, and on September 2, 2026, it sold 450 shares at $4.53 per share, resulting in a net purchase of 1,340 shares. No Rule 10b5-1 trading plan is reported.
Tenon Medical, Inc. (TNON) is registering up to 1,836,046 shares of common stock for resale by existing holders, primarily from prior private placements, equity compensation and the SiVantage asset acquisition. This is a resale registration; Tenon is not selling shares directly in this offering.
The registered shares include up to 597,610 Pre-Funded Warrant Shares, 1,058,517 August 2026 Series A Warrant Shares, 63,380 November 2025 Shares, related 63,380 November 2025 Warrant Shares, and smaller grants to executives, an employee and SiVantage. Assuming full exercise of the covered warrants and issuance of all SV Milestone Shares, Tenon expects 2,768,975 shares outstanding.
The company will receive no proceeds from stockholder resales, but may receive cash only upon exercise of the November 2025 and August 2026 warrants, which could total up to $7.9 million, intended for debt repayment, working capital and general corporate purposes. All share and per‑share data reflect a 1‑for‑35 reverse stock split effective August 10, 2026. Tenon’s auditors have issued an opinion on its 2024–2025 financial statements that includes substantial doubt about its ability to continue as a going concern.
Tenon Medical, Inc. (TNON) reported insider trading activity by ten percent owner HRT FINANCIAL LP in its common stock. On August 28, 2026, HRT purchased 12,376 shares at $5.21 and 5,981 shares at $6.35, and sold 4,932 shares at $7.07 and 2,091 shares at $7.90. On August 31, 2026, it sold an additional 1,276 shares at $4.66. Prices are per-share open-market or private transaction figures, and the filing does not state HRT’s post-transaction holdings.
Tenon Medical, Inc. (TNON) entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded and Series A warrants, which closed on August 31, 2026. The deal covers pre-funded warrants to purchase up to 597,610 shares of common stock at $5.019 per pre-funded warrant and Series A warrants to purchase up to 1,058,517 shares at an exercise price of $5.02 per share, generating gross proceeds of $2,999,404.59 (plus up to $597.61 upon pre-funded warrant exercise).
The Series A warrants are immediately exercisable for five years, subject to a 4.99%–9.99% beneficial ownership cap, while the pre-funded warrants are exercisable at $0.001 per share with a 9.99% cap. Tenon agreed to pay WallachBeth Capital a 7% cash fee on gross proceeds and to file a resale registration statement for the underlying shares within 15 days, targeting effectiveness within 45 days (or 75 days after a full SEC review). Tenon plans to use net proceeds for repayment of certain debt, working capital and general corporate purposes.
Tenon Medical, Inc. (TNON) had a Form 4 filed by reporting person HRT FINANCIAL LP, identified as a ten percent owner. On 2026-08-27, HRT FINANCIAL LP reported a sale of 419 shares of common stock at $4.96 per share, leaving 9,604 shares held directly. A footnote states that the transaction resulted in short sales, and that full price details by execution are available upon request to specified parties.
Tenon Medical, Inc. (TNON) received an initial insider ownership report from HRT FINANCIAL LP, which is identified as a ten percent owner. The filing lists 9,185 shares of Common Stock held directly after the reported position, with a related footnote stating that this position is "resulting in short sales." No specific buy or sell transactions are reported, only the resulting holdings.